CORRESP Filing
Coeptis Therapeutics Holdings, Inc.
Date: April 18, 2025 · CIK: 0001759186 · Accession: 0001683168-25-002684
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284230
Letter
Coeptis Therapeutics Holdings, Inc.
105 Bradford Rd, Suite 420
Wexford, Pennsylvania 15090
April 18, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549
Attention: Joshua Gursky
Re: Coeptis Therapeutics Holdings, Inc.
Registration Statement on Form S-1
Filed on January 10, 2025
File No. 333-284230
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, Coeptis Therapeutics Holdings, Inc., a Delaware corporation (the "Registrant"), hereby requests acceleration of the effective date of the above-referenced Registration Statement such that it may become effective on Monday, April 21, 2025, at 5:00 p.m. Eastern Time.
The Registrant hereby acknowledges that:
(i) should the Securities and Exchange Commission (the "Commission") or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
(ii) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
(iii) the Registrant may not assert the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Meister Seelig & Fein PLLC , by calling Denis Dufresne at (212) 655-3548 (also can be reached at dad@msf-law.com).
Thank you for your assistance in this matter.
Very truly yours,
COEPTIS
THERAPEUTICS HOLDINGS, Inc.
Show Raw Text
CORRESP 1 filename1.htm Coeptis Therapeutics Holdings, Inc. 105 Bradford Rd, Suite 420 Wexford, Pennsylvania 15090 April 18, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attention: Joshua Gursky Re: Coeptis Therapeutics Holdings, Inc. Registration Statement on Form S-1 Filed on January 10, 2025 File No. 333-284230 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, Coeptis Therapeutics Holdings, Inc., a Delaware corporation (the "Registrant"), hereby requests acceleration of the effective date of the above-referenced Registration Statement such that it may become effective on Monday, April 21, 2025, at 5:00 p.m. Eastern Time. The Registrant hereby acknowledges that: (i) should the Securities and Exchange Commission (the "Commission") or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement; (ii) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and (iii) the Registrant may not assert the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Meister Seelig & Fein PLLC , by calling Denis Dufresne at (212) 655-3548 (also can be reached at dad@msf-law.com). Thank you for your assistance in this matter. Very truly yours, COEPTIS THERAPEUTICS HOLDINGS, Inc. By: /s/ David Mehalick Name: David Mehalick Title: Chief Executive Officer cc: Denis Dufresne, Esq., Meister Seelig & Fein PLLC